Company intelligence / Profile preview
Eight Plus One Pharmaceutical
Chinapharm81.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Eight Plus One Pharmaceutical has several drug candidates in development with the most advanced programs in Phase 2 clinical trials targeting cardiovascular diseases such as stable angina and reperfusion injury. Other programs are at earlier stages including preclinical oncology and sepsis assets. No approved drugs or pivotal late-stage results were identified as of the latest data.
- Therapeutic areas
- OncologyCardiovascularInfectious Diseases
- Modalities
- Small moleculeSynthetic peptideBiological product
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Eight Plus One Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eight Plus One Pharmaceutical.